{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T23:38:17Z","timestamp":1722123497378},"reference-count":40,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2017,10,3]]},"DOI":"10.1080\/13696998.2017.1357563","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T07:17:43Z","timestamp":1500448663000},"page":"1066-1073","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy"],"prefix":"10.1080","volume":"20","author":[{"given":"Moushmi","family":"Singh","sequence":"first","affiliation":[{"name":"ICON Health Economics, London, UK;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Mealing","sequence":"additional","affiliation":[{"name":"ICON Health Economics, Abingdon, Oxfordshire, UK;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Baculea","sequence":"additional","affiliation":[{"name":"Janssen-Cilag, High Wycombe, Bucks, UK;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Cote","sequence":"additional","affiliation":[{"name":"Janssen-Cilag, High Wycombe, Bucks, UK;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Whelan","sequence":"additional","affiliation":[{"name":"Textpharm Ltd, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,8,9]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","volume":"26","author":"Eichhorst B","year":"2016","journal-title":"Ann Oncol"},{"key":"CIT0002","unstructured":"SEER. SEER. Prevalence database: \u201cUS Estimated 37-year L-D prevalence counts on 1\/1\/2012\u201d. National Cancer Institute, DCCPS, Surveillance Research Program, Data Modeling Branch, released April 2015, based on the November 2014 SEER data submission. 2012. http:\/\/surveillance.cancer.gov\/prevalence\/canques.html. [Last ccessed 8 February 2016]"},{"key":"CIT0003","unstructured":"European Medicines Agency. Medicines for rare diseases. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/special_topics\/general\/general_content_000034.jsp. [Last accessed August 2016]"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-207126"},{"key":"CIT0005","unstructured":"Mir MA. Chronic lymphocytic leukemia. Medscape Drugs and Diseases [Internet]; 2016. http:\/\/emedicine.medscape.com\/article\/199313-overview"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.0680"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-015-1039-y"},{"key":"CIT0009","unstructured":"National Comprehensive Cancer Center Network. Clinical practice guidelines in oncology: Non-Hodgkin\u2019s Lymphomas, v3.2016; 2016. www.nccn.org"},{"key":"CIT0010","unstructured":"Gilead Sciences Ltd. Zydelig (idelalisib): Summary of product characteristics; 2016. https:\/\/www.medicines.org.uk\/emc\/medicine\/29201. [Last accessed 14 June 2017]"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"CIT0012","first-page":"158","volume":"2013","author":"Shanafelt T.","year":"2013","journal-title":"ASH Education Program Book"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701724785"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.1317"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"CIT0017","volume-title":"A Bayesian network meta-analysis (NMA) of therapies for treatment-na\u00efve chronic lymphocytic leukemia (TN-CLL) patients ineligible for full-dose fludarabine therapy. ISPOR 22nd Annual International Meeting 2017","author":"Xu Y"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.12.001"},{"key":"CIT0019","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood.V124.21.4684.4684","volume":"124","author":"\u00d6sterborg A","year":"2014","journal-title":"Blood"},{"key":"CIT0020","unstructured":"Jones JJ, Wach M, Robak T, et\u00a0al. Results of a phase 3 randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL). ASCO Annual Meeting. Chicago, IL, USA. 29 May-2 June 2015"},{"key":"CIT0021","unstructured":"National Institute for Health and Care Excellence (NICE). TA 343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia; 25 April 2017. http:\/\/www.nice.org.uk\/guidance\/TA343\/Evidence"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.961012"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-50"},{"key":"CIT0024","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1182\/blood.V120.21.3926.3926","volume":"120","author":"Kay NE","year":"2015","journal-title":"Blood"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.08.2267"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.656106"},{"key":"CIT0027","unstructured":"Barr PM, Kipps T, Robak T, et\u00a0al. Improvement in hematologic function, disease burden\/symptoms with ibrutinib in older treatment-na\u00efve (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2. Annual Scientific Meeting of the American Geriatrics Society (AGS); Long Beach, FL, USA. May 2016"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.2165\/11588250-000000000-00000"},{"key":"CIT0029","unstructured":"Ghia P, Tedeschi A, Barr PM, et\u00a0al. Improvement in quality of life and well-being in older patients with treatment-na\u00efve (TN) CLL: Results from the randomized phase 3 study of ibrutinib (IBR) versus chlorambucil (CLB) (RESONATE-2). European Haematology Association Annual Meeting, Copenhagen, Denmark, 10 June 2016"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-206185"},{"key":"CIT0031","volume-title":"Fludarabine as first line therapy for chronic lymphocytic leukaemia. Report 42","author":"Hancock SWB","year":"2002"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2856"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-012-0419-2"},{"key":"CIT0035","volume-title":"Appraisal consultation document: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia","author":"National Institute for Health and Care Excellence (NICE)","year":"2014"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.03.535"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.03.1389"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8389"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60027-7"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00307-0"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2017.1357563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T17:20:47Z","timestamp":1599412847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2017.1357563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,9]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10,3]]}},"alternative-id":["10.1080\/13696998.2017.1357563"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2017.1357563","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}